Literature DB >> 16456878

Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population.

John D Seeger1, William A West, Daniel Fife, Gary J Noel, Larry N Johnson, Alexander M Walker.   

Abstract

BACKGROUND: Case reports and observational studies have implicated fluoroquinolone antibiotic exposure as a risk factor for Achilles tendon rupture (ATR), an uncommon condition for which there are few formal studies. We sought to quantify the strength of association between exposure to fluoroquinolone antibiotics and the occurrence of ATR, accounting for other risk factors.
METHODS: This was a case-control study nested within a health insurer cohort. Cases of ATR were identified and confirmed using patterns of health insurance claims that were validated through sampled medical record review. Information on risk factors, including fluoroquinolone exposure, came from health insurance claims.
RESULTS: There were 947 cases of ATR and 18 940 controls. A dispensing of a fluoroquinolone antibiotic in the past 6 months was more common among ATR cases than controls, although not significantly so (odds ratio (OR) = 1.2; 95% confidence interval (CI) = 0.9-1.7), and exposure to a higher cumulative fluoroquinolone dose was more strongly associated (OR = 1.5, 95%CI = 1.0-2.3). Other risk factors for ATR were trauma (OR = 17.2, 95%CI = 14.0-20.2), male sex (OR = 3.0, 95%CI = 2.6-3.5), injected corticosteroid administration (OR = 2.2, 95%CI = 1.6-2.9), obesity (OR = 2.0, 95%CI = 1.2-3.1), rheumatoid arthritis (OR = 1.9, 95%CI = 1.0-3.7), skin or soft tissue infections (OR = 1.5, 95%CI = 0.9-2.3), oral corticosteroids (OR = 1.4, 95%CI = 1.0-1.8), and non-fluoroquinolone antibiotics (OR = 1.2, 95%CI = 1.1-1.5).
CONCLUSIONS: The elevation in ATR risk associated with fluoroquinolones was similar in magnitude to that associated with oral corticosteroids or non-fluoroquinolone antibiotics. Trauma and male sex were more strongly associated with ATR, as were obesity and injected corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16456878     DOI: 10.1002/pds.1214

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  28 in total

1.  Operative versus nonoperative treatment for acute Achilles tendon rupture: a meta-analysis based on current evidence.

Authors:  Nan Jiang; Bowei Wang; Anfu Chen; Fu Dong; Bin Yu
Journal:  Int Orthop       Date:  2011-12-09       Impact factor: 3.075

2.  Early steps in the development of a claims-based targeted healthcare safety monitoring system and application to three empirical examples.

Authors:  Peter M Wahl; Joshua J Gagne; Thomas E Wasser; Debra F Eisenberg; J Keith Rodgers; Gregory W Daniel; Marcus Wilson; Sebastian Schneeweiss; Jeremy A Rassen; Amanda R Patrick; Jerry Avorn; Rhonda L Bohn
Journal:  Drug Saf       Date:  2012-05-01       Impact factor: 5.606

3.  The Risk of Fluoroquinolone-induced Tendinopathy and Tendon Rupture: What Does The Clinician Need To Know?

Authors:  Grace K Kim
Journal:  J Clin Aesthet Dermatol       Date:  2010-04

4.  Evidence of tendinitis provoked by fluoroquinolone treatment: a case-control study.

Authors:  Giovanni Corrao; Antonella Zambon; Lorenza Bertù; Anna Mauri; Valentina Paleari; Camillo Rossi; Mauro Venegoni
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

5.  Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.

Authors:  Manjunath P Pai; Piergiorgio Cojutti; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

6.  Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders.

Authors:  Barton L Wise; Christine Peloquin; Hyon Choi; Nancy E Lane; Yuqing Zhang
Journal:  Am J Med       Date:  2012-09-28       Impact factor: 4.965

Review 7.  Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components.

Authors:  Alison E Barnhill; Matt T Brewer; Steve A Carlson
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

Review 8.  Predictors of primary Achilles tendon ruptures.

Authors:  Femke M A P Claessen; Robert-Jan de Vos; Max Reijman; Duncan E Meuffels
Journal:  Sports Med       Date:  2014-09       Impact factor: 11.136

9.  Interleukins 4 and 13 modulate gene expression and promote proliferation of primary human tenocytes.

Authors:  Jean-Paul Courneya; Irina G Luzina; Cynthia B Zeller; Jeffrey F Rasmussen; Alexander Bocharov; Lew C Schon; Sergei P Atamas
Journal:  Fibrogenesis Tissue Repair       Date:  2010-06-10

10.  Levofloxacin-induced Achilles tendinitis in a young adult in the absence of predisposing conditions.

Authors:  Areum Durey; Yong Soo Baek; Jin Seok Park; Kwangsoo Lee; Jeong-Seon Ryu; Jin-Soo Lee; Moon-Hyun Cheong
Journal:  Yonsei Med J       Date:  2010-05       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.